Elucid | Visualize Lesion-level Plaque Composition

From Lesion-Level Risk to Patient-Level Impact

Enabling patient-specific treatment pathways.

FFR‑CT and Stenosis Under FDA Review

High-Risk Plaque is the Strongest Predictor of Heart Attack and Stroke

Cardiovascular disease is the most common cause of death and disability globally, largely driven by myocardial infarction (MI) and ischemic stroke.¹ Despite advances in therapies, many high‑risk patients remain undiagnosed until they experience serious cardiac events. While traditional clinical guidelines for coronary artery disease begin with identifying patient risk factors, such as age, diet, and lifestyle, the strongest predictor of MI is atherosclerosis (plaque build-up in the arteries) – not only total plaque, but specific types of high-risk plaques that are more likely to rupture, such as Lipid Rich Necrotic Core (LRNC).^2,3

Enabling Patient-Specific Treatment Pathways

Elucid’s comprehensive clinical platform offers histology-validated plaque analysis including lipid-rich necrotic core, biology-based FFR‑CT, and stenosis⁵, and a new user interface to be best in class for information to clinical insights. Together, Elucid’s platform offers unmatched accuracy, reproducibility and transparency with key clinical insights to empower physicians to deliver lesion-level, personalized cardiovascular care.

The Myocardial Infarction Paradox

Patients deemed “low risk” still account for nearly half of all heart attacks. A recent study led by Mount Sinai researchers finds that following current screening guidelines may cause missed opportunities for early detection of heart attacks and prevention. Addressing this gap will require a paradigm shift from short-term, age-weighted risk prediction toward lifetime, disease-oriented prevention. Integrating imaging, biomarkers, and novel risk factors may help uncover subclinical disease earlier, when intervention yields the greatest benefit.⁴

FFR‑CT and Stenosis Under FDA Review

What Physicians are Saying

"The Lesion Inspection Tool in Plaque-IQ provides a detailed view of plaque composition at the lesion level, beyond giving just overall plaque metrics. Because cardiovascular events like heart attacks occur at the lesion level, having the ability to characterize individual lesions enhances my understanding of a patient’s disease process and supports more informed clinical decision-making."

"Plaque analysis is quickly becoming an essential tool in my overall patient diagnosis and management, and its adoption will only accelerate as coverage continues to expand. I’m particularly intrigued by Elucid‘s histology-based technology and Plaque-IQ’s ability to identify lipid rich necrotic core (LRNC). This additional insight is influencing my diagnostic decisions and shaping how I manage patient care."

"The ability to characterize plaque composition precisely revolutionizes carotid stroke risk assessment. Plaque composition has long been recognized as a critical risk element for stroke but was not available with conventional imaging techniques. Precise determination of plaque composition supersedes the traditional stenosis assessment and allows a more accurate identification of patients at highest risk for carotid stroke and facilitates procedural choice and planning."

"For years, we’ve used CT to quantify coronary plaque and personalize prevention and, now, being able to do the same with the carotid arteries is a game-changer. This technology finally lets us measure and monitor carotid plaque biology, not just anatomy, giving us a much more complete picture of stroke risk and overall vascular health. This is truly the future of vascular medicine."

See the Elucid Difference

Contact us today to learn more about Elucid or to schedule a product demo

References

¹World Health Organization (WHO), Cardiovascular diseases (CVDs). 2017 23, April 2020. Available from: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).

² https://www.ahajournals.org/doi/10.1161/01.ATV.20.5.1262

³https://pubmed.ncbi.nlm.nih.gov/39600843/

⁴ Mueller, A. S., Leipsic, J, et. al. Limitations of Risk- and Symptom-Based Screening in Predicting First Myocardial Infarction. JACC: Advances, vol 4, number 12,part 2, 1 December 2025. https://www.jacc.org/doi/10.1016/j.jacadv.2025.102361

⁵ FFR‑CT and Stenosis pending FDA review